登记标题:AI 生成的译文,英文原文附后,以原文为准
QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌AI 译文
“QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.”
ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 17 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 18
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
- 研究中心贵州医科大学附属肿瘤医院Affiliated Cancer Hospital of Guizhou Medical University贵阳医院页面
- 研究中心东莞市人民医院Dongguan People's Hospital东莞医院页面
- 研究中心复旦大学附属眼耳鼻喉科医院Eye & ENT Hospital of Fudan University上海医院页面
- 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
- 研究中心佛山市第一人民医院First People's Hospital of Foshan佛山医院页面
- 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
- 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
- 研究中心广州医科大学附属番禺中心医院Guangzhou Panyu Central Hospital广州医院页面
- 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
- 研究中心江苏省肿瘤医院Jiangsu Cancer Hospital南京医院页面
- 研究中心武汉大学人民医院Renmin Hospital of Wuhan University武汉医院页面
- 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
- 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
- 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
- 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
- 研究中心中山市人民医院Zhongshan City People's Hospital中山医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06749899,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 65 岁;性别:不限
登记记录的入选字段
Patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma according to WHO criteria.
入选标准第 2 条
Tumor staged as T4N1 and T1-4N2-3 (AJCC 9th)
入选标准第 3 条
Stage II: T1-3N2
入选标准第 4 条
Stage III: T1-4N3, T4N1-2
入选标准第 5 条
Women of childbearing potential (WOCBP) must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of study drug (e.g., condoms, physician-guided regular use of oral contraceptives).
入选标准第 18 条
Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
入选标准第 9 条
Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) ≤2.5×ULN
入选标准第 10 条
Alkaline phosphatase ≤ 2.5 × ULN
入选标准第 11 条
Positive for hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA >1×103 copies/mL, positive for anti-hepatitis C virus (HCV) antibody , positive for anti-hepatitis C virus (HCV) antibody
排除标准第 1 条
Positive for anti-HIV antibody or diagnosed with acquired immunodeficiency syndrome (AIDS).
排除标准第 2 条
Pregnant or breastfeeding women (pregnancy testing should be considered for women of childbearing potential with active sexual life)
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06749899,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥18 and ≤65 years Patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma according to WHO criteria. Tumor staged as T4N1 and T1-4N2-3 (AJCC 9th) Stage II: T1-3N2 Stage III: T1-4N3, T4N1-2 Eastern Cooperative Oncology Group performance score of 0-11. Adequate marrow function: white blood cell count > 4 × 10⁹/Lhemoglobin >90g/L and platelet count >100×10⁹/L Adequate hepatic and renal function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN) Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) ≤2.5×ULN Alkaline phosphatase ≤ 2.5 × ULN clearance rate ≥ 60 ml/min Other laboratory and clinical criteria Normal thyroid function, serum amylase and lipase, pituitary hormone levels, inflammatory markers, cardiac enzyme tests and electrocardiogram (ECG) For patients aged >50 years with a history of smoking, normal pulmonary function test (PFT) results are required For patients with abnormal ECG findings or a prior history of cardiovascular disease (not meeting any exclusion criteria listed in Item 8), additional assessments including myocardial function evaluation and cardiac ultrasound (echocardiography) must be performed, with results within normal limits Patients must be informed of the investigational nature of this study and give written informed consent, and be willing and able to comply with the study schedule, including follow-up visits, treatment procedures, laboratory testing, and other protocol-related requirements. Women of childbearing potential (WOCBP) must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of study drug (e.g., condoms, physician-guided regular use of oral contraceptives).排除标准:Exclusion Criteria:
Positive for hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA >1×103 copies/mL, positive for anti-hepatitis C virus (HCV) antibody , positive for anti-hepatitis C virus (HCV) antibody Positive for anti-HIV antibody or diagnosed with acquired immunodeficiency syndrome (AIDS). Active pulmonary tuberculosis: Patients with a history of active tuberculosis within the past year should be excluded regardless of treatment status. Patients with a history of active pulmonary tuberculosis more than one year prior should also be excluded, unless they received confirmed and regular anti-tuberculosis treatment. Active, known, or suspected autoimmune diseases, including but not limited to uveitis, colitis, hepatitis, hypophysitis, nephritis, vasculitis, systemic lupus erythematosus, hyperthyroidism, hypothyroidism, and asthma requiring bronchodilators. Type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) are allowed. Thymic epithelial tumors (TETs), including thymoma, thymic carcinoma, and thymic neuroendocrine tumors (NETTs). History of interstitial lung disease or pneumonia requiring oral or intravenous corticosteroids within the past year; use of vancomycin within the past month. Ongoing chronic systemic corticosteroid therapy (equivalent to or greater than prednisone >10mg per day) or any other immunosuppressive therapy. Patients received inhale or topical corticosteroid are allowed. Uncontrolled cardiac conditions, such as: Heart failure with New York Heart Association (NYHA) classification ≥ Class II; Unstable angina; History of myocardial infarction within the past year; Supraventricular or ventricular arrhythmias requiring treatment or intervention Pregnant or breastfeeding women (pregnancy testing should be considered for women of childbearing potential with active sexual life) History or presence of other malignancies, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma. Known hypersensitivity to macromolecule protein products or any component of QL1706. Active infections requiring systemic treatment within 1 week prior to enrollment. Administration of live vaccines within 30 days prior to the first dose of epalurilimab-tovorolimab. History of organ transplantation or hematopoietic stem cell transplantation. Any other condition assessed by the investigator as potentially compromising patient safety or compliance, such as severe illnesses requiring urgent treatment (including psychiatric disorders), significantly abnormal laboratory values, or other psychological, familial, or social risk factors.
引自 ClinicalTrials.gov, NCT06749899, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06749899,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。